192 related articles for article (PubMed ID: 31155437)
1. Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ≤10 ng/ml at initial biopsy.
Lin CY; Wang SS; Yang CK; Li JR; Chen CS; Hung SC; Chiu KY; Cheng CL; Ou YC; Yang SF
Urol Oncol; 2019 Nov; 37(11):814.e9-814.e16. PubMed ID: 31155437
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Shen HP; Hsiao YH; Yang SF; Liu YF; Ko JL; Wang PH
Int J Med Sci; 2018; 15(6):587-594. PubMed ID: 29725249
[TBL] [Abstract][Full Text] [Related]
3. The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Smith AD; Truong M; Bristow R; Yip P; Milosevic MF; Joshua AM
Anticancer Res; 2016 Sep; 36(9):4489-92. PubMed ID: 27630286
[TBL] [Abstract][Full Text] [Related]
4. Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan.
Chien MH; Yang JS; Chu YH; Lin CH; Wei LH; Yang SF; Lin CW
PLoS One; 2012; 7(12):e51051. PubMed ID: 23226559
[TBL] [Abstract][Full Text] [Related]
5. 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
Hua KT; Liu YF; Hsu CL; Cheng TY; Yang CY; Chang JS; Lee WJ; Hsiao M; Juan HF; Chien MH; Yang SF
Sci Rep; 2017 Jun; 7(1):4466. PubMed ID: 28667334
[TBL] [Abstract][Full Text] [Related]
6. Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Wang SS; Liu YF; Ou YC; Chen CS; Li JR; Yang SF
PLoS One; 2013; 8(12):e82804. PubMed ID: 24349364
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
8. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
Wilczak W; Wittmer C; Clauditz T; Minner S; Steurer S; Büscheck F; Krech T; Lennartz M; Harms L; Leleu D; Ahrens M; Ingwerth S; Günther CT; Koop C; Simon R; Jacobsen F; Tsourlakis MC; Chirico V; Höflmayer D; Vettorazzi E; Haese A; Steuber T; Salomon G; Michl U; Budäus L; Tilki D; Thederan I; Fraune C; Göbel C; Henrich MC; Juhnke M; Möller K; Bawahab AA; Uhlig R; Adam M; Weidemann S; Beyer B; Huland H; Graefen M; Sauter G; Schlomm T
Eur Urol; 2018 Sep; 74(3):376-386. PubMed ID: 29908878
[TBL] [Abstract][Full Text] [Related]
9. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
[TBL] [Abstract][Full Text] [Related]
10. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
11. The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.
Izumi K; Ikeda H; Maolake A; Machioka K; Nohara T; Narimoto K; Ueno S; Kadono Y; Kitagawa Y; Konaka H; Mizokami A; Namiki M
Prostate; 2015 Jul; 75(10):1034-42. PubMed ID: 25753899
[TBL] [Abstract][Full Text] [Related]
12. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Eckert AW; Horter S; Bethmann D; Kotrba J; Kaune T; Rot S; Bache M; Bilkenroth U; Reich W; Greither T; Wickenhauser C; Vordermark D; Taubert H; Kappler M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654595
[TBL] [Abstract][Full Text] [Related]
14. Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics.
Lin CY; Wang SS; Yang CK; Li JR; Chen CS; Hung SC; Chiu KY; Cheng CL; Ou YC; Yang SF
Int J Med Sci; 2019; 16(11):1424-1429. PubMed ID: 31673232
[TBL] [Abstract][Full Text] [Related]
15. The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
Reyes-Hernández OD; Vega L; Jiménez-Ríos MA; Martínez-Cervera PF; Lugo-García JA; Hernández-Cadena L; Ostrosky-Wegman P; Orozco L; Elizondo G
PLoS One; 2014; 9(6):e99974. PubMed ID: 24924803
[TBL] [Abstract][Full Text] [Related]
16. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml.
Ou YC; Chen JT; Cheng CL; Ho HC; Yang CR
Jpn J Clin Oncol; 2003 Nov; 33(11):574-9. PubMed ID: 14711982
[TBL] [Abstract][Full Text] [Related]
18. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.
Gu C; Qu Y; Zhang G; Sun L; Zhu Y; Ye D
Oncotarget; 2015 Oct; 6(31):32205-11. PubMed ID: 26320190
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
20. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
